TAAR1 and schizophrenia: The TAAR1 partial agonist ralmitaront (RO6889450; Roche, Basel, Switzerland) is recruiting for a phase 2 trial in patients with schizophrenia or schizoaffective disorder with negative symptoms (NCT03669640; Table 1), although a different phase 2 trial in patients with an acute exacerbation of schizophrenia or schizoaffective disorder was terminated early after it failed to meet the primary endpoint (change from baseline in PANSS total score, NCT04512066).